Dr Zhinan Xia
Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.
Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.
Moderna
Head of BiotherapeuticsMr Eric Yhap
ClinSmart is known as a trusted partner for both simple and comprehensive development programs required by biopharmaceutical and medical device companies, since 1994. Our academically and industry trained staff, combined and supported by the latest proven technologies, focuses on improving the efficiency of clinical development while minimizing risk and costs. We guarantee upfront strategic clinical planning, high quality regulatory packages including risk mitigation strategies prior to the start of any project, organizational structure which results in lower costs than a large CRO, global capabilities, and overall clinical and scientific expertise. Our experienced staff will work closely with your team to understand the requirements of your development program and will ensure that the right team is put into place to accomplish the tasks at hand.
For more information about our team and services, please visit our website (www.clinsmart.com) and LinkedIn page.
Mr Gary Zammit
If you’ve been looking for something different from your CRO, choose the one that stands out.
Welcome to Clinilabs, where science leads business.
Clinilabs is a premier full-service CRO that specializes in applying scientific principles to phase I, II, and III studies in order to bring investigational products to the threshold of successful approval. Our unique development strategy builds value into early phase development programs, carrying promising products forward swiftly and abandoning failures early. We enable our clients to apply their resources wisely and maximize the value of their drug and device portfolios.
Expect something different from your CRO – Science. Communication. Collaboration. Results.
Clinilabs
President & CEOStephen Harvey . Zinner, M.D
Mount Auburn Hospital was founded in 1886 as the first hospital in Cambridge, Massachusetts. Over the years, generations of committed individuals have dedicated their careers to achieving the vision of being the best community teaching healthcare system in the Boston area. On a mission to improve the health of the residents of Cambridge and surrounding communities, Mount Auburn Hospital is dedicated to delivering healthcare services in a personable, convenient, and compassionate manner, with respect for the dignity of patients and their families.
Mount Auburn Hospital is affiliated with Harvard Medical School, making significant contributions to educating the caregivers of tomorrow. The hospital is fully accredited by the Joint Commission on Accreditation of Healthcare Organizations and is a member of the American Hospital Association, the Council of Teaching Hospitals, and the Association of American Medical Colleges.
Mount Auburn provides a number of clinical services to Cambridge and surrounding communities, including cardiac catheterization, laboratory services, rehabilitation services, and specialized services for men, women and seniors.
Mount Auburn Hospital - Havard Medical School
Professor of Medicine - Department of MedicineDr Bhagwagar Zubin
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Alexion developed Soliris® (eculizumab) from the laboratory through commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening, ultra-rare disorders. Today, Soliris is approved in nearly 50 countries for PNH and nearly 40 countries for aHUS. Download Soliris prescribing information.
As we continue to expand our operations into additional countries, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Alexion is establishing a premier global metabolic rare disease franchise with two potential therapies in late-stage development, Strensiq™ (asfotase alfa) for hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL Deficiency, or LAL-D). Strensiq has been approved in the EU and Japan for the treatment of patients with HPP, and Kanuma has been approved in the EU for the treatment of patients with LAL-D. In addition, as the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms, including evaluating potential indications for Soliris in additional severe and ultra-rare disorders.
Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.
Our global headquarters and research operations are in Cheshire, Conn., and will move to New Haven, Conn. in 2015. Alexion's more than 2,800 employees serve patients in 50 countries.